5 research outputs found
Fracto-eutectogels: SDS fractal dendrites via counterion condensation in a deep eutectic solvent
Preparation of drug-loaded small unilamellar liposomes and evaluation of their potential for the treatment of chronic respiratory diseases
The aim of the present investigation was to evaluate the influence of liposome formulation on the
ability of vesicles to penetrate a pathological mucus model obtained from COPD affected patients in
order to assess the potential of such vesicles for the treatment of chronic respiratory diseases by
inhalation. Therefore, Small Unilamellar Liposomes (PLAIN-LIPOSOMEs), Pluronic® F127-
surface modified liposomes (PF-LIPOSOMEs) and PEG 2000PE-surface modified liposomes
(PEG-LIPOSOMEs) were prepared using the micelle-to-vesicle transition (MVT) method and
beclomethasone dipropionate (BDP) as model drug. The obtained liposomes showed diameters in
the range of 40-65 nm, PDI values between 0.25-0.30 and surface electric charge essentially close
to zero. The encapsulation efficiency was found to be dependent on the BDP/lipid ratio used and,
furthermore, BDP-loaded liposomes were stable in size both at 37°C and at 4°C. All liposomes
were not cytotoxic on H441 cell line as assessed by the MTT assay. The liposome uptake was
evaluated through a cytofluorimetric assay that showed a non-significant reduction in the
internalization of PEG-LIPOSOMEs as compared with PLAIN-LIPOSOMEs. The penetration
studies of mucus from COPD patients showed that the PEG-LIPOSOMEs were the most mucuspenetrating
vesicles after 27 hours. In addition, PEG- and PF-LIPOSOMEs did not cause any effect
on bronchoalveolar lavage fluid proteins after aerosol administration in the mouse. The results
highlight that PEG-LIPOSOMEs show the most interesting features in terms of penetration through
the pathologic sputum, uptake by airway epithelial cells and safety profile
Preparation of drug-loaded small unilamellar liposomes and evaluation of their potential for the treatment of chronic respiratory diseases
The aim of the present investigation was to evaluate the influence of liposome formulation on the
ability of vesicles to penetrate a pathological mucus model obtained from COPD affected patients in
order to assess the potential of such vesicles for the treatment of chronic respiratory diseases by
inhalation. Therefore, Small Unilamellar Liposomes (PLAIN-LIPOSOMEs), Pluronic® F127-
surface modified liposomes (PF-LIPOSOMEs) and PEG 2000PE-surface modified liposomes
(PEG-LIPOSOMEs) were prepared using the micelle-to-vesicle transition (MVT) method and
beclomethasone dipropionate (BDP) as model drug. The obtained liposomes showed diameters in
the range of 40-65 nm, PDI values between 0.25-0.30 and surface electric charge essentially close
to zero. The encapsulation efficiency was found to be dependent on the BDP/lipid ratio used and,
furthermore, BDP-loaded liposomes were stable in size both at 37°C and at 4°C. All liposomes
were not cytotoxic on H441 cell line as assessed by the MTT assay. The liposome uptake was
evaluated through a cytofluorimetric assay that showed a non-significant reduction in the
internalization of PEG-LIPOSOMEs as compared with PLAIN-LIPOSOMEs. The penetration
studies of mucus from COPD patients showed that the PEG-LIPOSOMEs were the most mucuspenetrating
vesicles after 27 hours. In addition, PEG- and PF-LIPOSOMEs did not cause any effect
on bronchoalveolar lavage fluid proteins after aerosol administration in the mouse. The results
highlight that PEG-LIPOSOMEs show the most interesting features in terms of penetration through
the pathologic sputum, uptake by airway epithelial cells and safety profile